Evidence map›Paper›PMID 35801361›Full record

ArticleActa ophthalmologica2023

A prognostic classification system for uveal melanoma based on a combination of patient age and sex, the American Joint Committee on Cancer and the Cancer Genome Atlas models.

Viktor T Gill, Shiva Sabazade, Christina Herrspiegel, Kathryn G Ewens, Adrianna Opalko, Nicole Dan, Tinna Christersdottir, Alexander Berg Rendahl, Carol L Shields, Stefan Seregard and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Acta ophthalmologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Pathological and Molecular Diagnosis of Uveal Melanoma.Diagnostics (Basel, Switzerland) · 2024
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Viktor T GillDepartment of Pathology, Västmanland Hospital Västerås, Västerås, Sweden.
Shiva SabazadeDepartment of Clinical Neuroscience, Division of Eye and Vision, Karolinska Institutet, Stockholm, Sweden.
Christina HerrspiegelDepartment of Clinical Neuroscience, Division of Eye and Vision, Karolinska Institutet, Stockholm, Sweden.
Kathryn G EwensDepartment of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Adrianna OpalkoSt. Erik Eye Hospital, Stockholm, Sweden.
Nicole DanSt. Erik Eye Hospital, Stockholm, Sweden.
Tinna ChristersdottirDepartment of Clinical Neuroscience, Division of Eye and Vision, Karolinska Institutet, Stockholm, Sweden.
Alexander Berg RendahlDepartment of Clinical Neuroscience, Division of Eye and Vision, Karolinska Institutet, Stockholm, Sweden.
Carol L ShieldsOcular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Stefan SeregardDepartment of Clinical Neuroscience, Division of Eye and Vision, Karolinska Institutet, Stockholm, Sweden.
Arupa GangulyDepartment of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Gustav StålhammarDepartment of Clinical Neuroscience, Division of Eye and Vision, Karolinska Institutet, Stockholm, Sweden.ORCID https://orcid.org/0000-0001-9401-8911
Karolinska Institutet · SES:t Eriks Ögonsjukhus · SEUniversity of Pennsylvania · USThomas Jefferson University · US

Funding

Cancerfonden 20 0798 FkCarmen and Bertil Regnér's Foundation 2020-00062Karolinska Institutet 2020-013333Karolinska Institutet 2020-02517Ögonfonden 2020-04-27Region Stockholm 20200356Royal Swedish Academy of Sciences ME2019-0036Stiftelsen Kronprinsessan Margaretas Arbetsn ämnd för Synskadade 157Svenska Läkares ällskapet Cronqvists stiftelse SLS 934014
6 · The paper itself

Abstract

purposeTo revisit the independent importance of ciliary body involvement (CBI), monosomy 3 (M3), tumour size, histological and clinical factors in uveal melanoma (UM) and to devise a new prognostic classification based on a combination of the American Joint Committee on Cancer (AJCC) and the Cancer Genome Atlas (TCGA) models.

methodsTwo cohorts with a total of 1796 patients were included. Clinicopathological factors were compared between patients with and without CBI and M3. Development of the prognostic classification was performed in a training cohort and was then tested in two independent validation cohorts.

resultsTumours with CBI were more common in women, had greater apical thickness, greater basal tumour diameter, greater rates of vasculogenic mimicry and greater rates of M3, were more often asymptomatic at diagnosis and had poorer 5- and 10-year globe conservation rates (p < 0.023). In multivariate logistic regression, patient age at diagnosis, tumour diameter and CBI were independent predictors of M3 (p < 0.001). In multivariate Cox regression, male sex, age at diagnosis, tumour diameter, M3 and CBI were independent predictors of metastasis. The proposed prognostic classification combined patient age, sex, CBI, extraocular extension, M3, 8q (optional) and tumour size, and demonstrated greater prognostic acumen than both AJCC 4 T categories and TCGA groups A to D in validation cohorts.

conclusionsTumour size does not confound the prognostic implication of CBI, M3, male sex and age at diagnosis in UM. These factors were included in a new prognostic classification that outperforms AJCC T category and TCGA groups.

Indexed as

MelanomaUveal NeoplasmsFemaleHumansMaleMonosomyPrognosisRetrospective StudiesUnited StatesUveal Melanomaciliary body melanomahistologymonosomy 3oncologypathologyprognosissymptomsuveal melanomavasculogenic mimicry

Identifiers

PMID35801361
PMCPMC10083913
OpenAlexW4284888729

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.